@article { author = {}, title = {Prognostic Value of Phosphorylated mTOR/RPS6KB1 in Nonsmall Cell Lung Cancer}, journal = {Asian Pacific Journal of Cancer Prevention}, volume = {14}, number = {6}, pages = {3725-3728}, year = {2013}, publisher = {West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.}, issn = {1513-7368}, eissn = {2476-762X}, doi = {}, abstract = {Background: The mammalian target of rapamycin (mTOR) /RPS6KB1 activation has recently been implicatedin tumour development, but its role in lung cancer remains unclear. The aim of this study was to explore the roleof mTOR/RPS6KB1 signaling pathway in non-small-cell lung cancer (NSCLC). Methods: Immunohistochemistrywas performed to assess the expression of phosphorylated mammalian target of rapamycin (p-mTOR) and itsdownstream ribosomal phosphorylated RPS6KB1 (p-RPS6KB1) in NSCLC patients. We also analyzed p-mTOR/p-RPS6KB1 protein expression in 45 fresh NSCLC tissues using Western blotting. Results: The expressionlevel of p-mTOR and p-RPS6KB1 was significantly higher in NSCLC tumor specimens than that in adjacentnoncancerous normal lung tissues (P<0.01). p-mTOR expression correlated with p-RPS6KB1. Furthermore,high expression level of p-mTOR or p-RPS6KB1 in NSCLC was associated with a shorter overall survival (bothP<0.01). Multivariate analysis indicated high level of p-mTOR expression was an independent prognostic factor(HR=2.642, 95%CI 1.157–4.904, p=0.002). Conclusions: p-mTOR and p-RPS6KB1 could be useful prognosticmarkers for NSCLC.}, keywords = {non-small-cell lung cancer,Biomarker,mTOR/RPS6KB1,Prognosis}, url = {https://journal.waocp.org/article_27848.html}, eprint = {https://journal.waocp.org/article_27848_2ff912c9135f50324e859b36a0cc7055.pdf} }